To support Sanofi's strategic plan to develop the innovation and competitiveness of the Scoppito production plant. The Company is committed to the welfare of the local communities in which it operates, with the aim of maintaining the levels of employment stability and competitiveness of the area. Editor's note: Sanofi layoffs from 2010 to 2013.
(AGI) - Rome, July 22. – The prime minister, Matteo Renzi, in the presence of the minister of economic development, Federica Guidi, and the undersecretary to the presidency of the council, Graziano Delrio, signed a national development contract this morning which, among others, supports the strategic plan of Sanofi to develop the innovation and competitiveness of the Scoppito (L'Aquila) production plant. The Government has allocated a contribution of 4.3 million euros against the 28.3 invested by the Company. For Sanofi was present Arturo Zanni, president and managing director of the Group in Italy. "The pharmaceutical industry represents an excellence of Made in Italy and is an important lever for returning to growth: we are the second country in Europe for manufacturing capacity", declared Zanni. “The roots of Sanofi in our area, with no less than 6 production plants - he added - fits into a fertile context, which tells many stories of excellence that have involved generations of Italians. We thank the Renzi Government which has the merit of recognizing the strategic value of our sector and of implementing a development contract which we feel is particularly important for the rebirth of L'Aquila and the Abruzzo region”. The strategic plan of the Scoppito site envisages the implementation of innovative interventions - new technologies and new productions - to improve the capacity and quality of the processes, with the aim of locating productions currently made in foreign plants. Furthermore, the creation of a new department is planned to improve the competitiveness, operational efficiency, logistics and sustainability of the entire range of the Group's counter products through the introduction of new technologies.
The Scoppito plant represents one of Sanofi's strategic hubs for the production and packaging of solid oral products, with 4.6 billion tablets produced and over 121 million packs made in 2013, exported to over 90 countries. Due to its strategic centrality, the site was chosen for the production of the chewable tablets of the Maalox antacid, investing in the improvement of its already cutting-edge technological equipment and increasing its level of specialisation. Sanofi Italia is the largest industrial reality in the pharmaceutical sector in the country, both in terms of number of collaborators and volume of production. The Company has always been committed to the well-being of the local communities in which it operates, with the aim of maintaining the levels of employment stability and competitiveness of the territory.
(AGI) Etc
MEMORANDUM:
Sanofi-Pasteur: smooth as silk layoffs (2013)
Pharmaceuticals: "whistleblowers" halved In Sanofi 351 (2012)
Sanofi, announced 900 redundancies in France. Loud protests (2012)
Sanofi and his mutant fish (2012)
500 layoffs at Sanofi-Aventis. Reduction of the workforce of 10-15% in the scientific information area. (2011)
Pharma and layoffs. Sanofi: 2500 in France (2010)
Sanofi CEO Christopher Viehbacher
It is part of the Sanofi group Merial animal health division
Liliane Bettencourt, the richest woman in the world, through l'Oréal controls the 10.41% of Sanofi-Aventis,
TO
